Cryptocurrencies
Goldman Sachs sets new Biogen stock price target on bold Alzheimer’s bet
Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics and biosimilars, revenue has trended down, and the stock spent much of 2025 trading near Read more…